Multiple system atrophy

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PMN, MSA, Bioorganic chemistry, ALS, Multiple system atrophy, Zebrafish, SOD1, Neuroscience, Journal, Brain cell, TAR, Protein, Biochemistry, PROMIS, Antibody, Therapy, Vaccine

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

The MSA Coalition Announces Name Change to "Mission MSA"

Retrieved on: 
Monday, March 25, 2024
Multiple system atrophy, Mission, Education, Patient, Research, MSA, Management

MCLEAN, Va., March 25, 2024 /PRNewswire-PRWeb/ -- Today, The Multiple System Atrophy (MSA) Coalition, the leading organization dedicated to fighting multiple system atrophy, announces a transformative change in its identity. The organization's name is now Mission MSA, reflecting a more accurate representation of its goals and values and renewed commitment to its mission to lead the charge to cure MSA.

Key Points: 
  • Today, the MSA Coalition, the leading organization dedicated to fighting multiple system atrophy, announces a transformative change in its identity.
  • MCLEAN, Va., March 25, 2024 /PRNewswire-PRWeb/ -- Today, The Multiple System Atrophy (MSA) Coalition, the leading organization dedicated to fighting multiple system atrophy, announces a transformative change in its identity.
  • "Mission MSA reflects our core purpose to work towards finding a cure in the future and meeting the current needs of those living with MSA," says Joe Lindahl, Chief Executive Officer, Mission MSA.
  • "Mission MSA represents a collective effort to lead the charge against multiple system atrophy," says Pam Bower, Chairperson of the Mission MSA Board of Directors.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Tuesday, February 27, 2024
Master of Science, PD, Doctor of Philosophy, Medical school, GBA, Alpha-synuclein, Conference, EMBA, Parkinson's disease, Medical University of Innsbruck, Biomarker, Mayo Clinic, Multiple system atrophy, Patient, Dementia, Synucleinopathy, Development, DSM-IV codes, Lewy body, Biogen, Management

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Tuesday, February 20, 2024
Molecule, SAN, MSA, Treatment, Conceptual model, Iron, Multiple system atrophy, Annual general meeting, AAN, ASX, ATH, Therapy, Disease, Vanderbilt University, American Academy, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company’s development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.
  • “We are thrilled to be presenting at this prestigious international neurology conference, including new baseline biomarker data on ATH434 from our ongoing Phase 2 randomized, double blind clinical trial in multiple system atrophy (MSA), as well as compelling preclinical primate data on ATH434 in Parkinson’s disease,” said, David Stamler, M.D., Chief Executive Officer of Alterity.
  • “In addition, we remain in the vanguard of biomarker evaluation of MSA, as our partners at Vanderbilt University will present important data from our bioMUSE natural history study.
  • AAN promises to be a very productive conference for us as we advance our MSA program toward data later this year and expand our development toward Parkinson’s disease.”
    A Phase 2 Study of ATH434, a Novel Inhibitor of α-Synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA)
    Effects of ATH434, a Clinical-phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques

First Watch Co-Founder, Longtime CEO and Former Chairman Ken Pendery Passes Away at 70

Retrieved on: 
Tuesday, March 5, 2024
Steps, Restaurant, Breakfast, Multimedia, Home Office, Culture, Neurological disorder, Multiple system atrophy, Commitment, First Watch, Family, Red, Maureen, Trust, Management

BRADENTON, Fla., March 5, 2024 /PRNewswire/ -- His bold words are plastered on the walls of the Florida-based restaurant company's Home Office and serve as a constant reminder and permanent edict from the beloved hospitality leader: "Culture is integrity. It's honesty. It's respect."

Key Points: 
  • First Watch announced today that co-founder and longtime leader Ken Pendery passed away on March 4, 2024, after a battle with Multiple System Atrophy, a rare neurological disorder.
  • Pendery retired from the company's board of directors in 2022 after 38 years with the breakfast, brunch and lunch concept.
  • During his time at the helm, First Watch grew from about 50 restaurants in 1998 to more than 330 in 2018, when he transitioned from CEO to executive chairman.
  • Pendery is survived by his wife, Jenny; two children, Trey (Maureen) and Libby (Kevin); and four grandchildren, Woods, Nora, Sita and Red.

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Retrieved on: 
Monday, January 22, 2024
Canada Research Chair, Multiple system atrophy, Patient, Biology, Emeritus, Research, Associate, Dementia, University, Neurochemistry, PMN, Cell biology, American Academy, Epitope, Vaccine, MSA, Anatomy, Physiology, Neurodegenerative disease, Microbiology, Vaccination, AAN, Immunology, PROMIS, Neuroscience, Therapy, Synucleinopathy, CAD, VIDO

“We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.
  • Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado.

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Retrieved on: 
Monday, January 22, 2024
ASX, Multiple system atrophy, Pathology, Patient, Therapy, Neurology, SAN, ATH, Orphan, Civil service commission, European Commission, Element, Iron, MSA, Quality of life, ODD, Disease, Central nervous system, FDA, Biomarker, Frasier, Clinical trial, Brain, Vanderbilt University Medical Center, Blood pressure, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.

Key Points: 
  • As we begin a new year, I wanted to take a moment to thank you for your support of Alterity, reflect on our accomplishments in 2023, and lay out our key milestones for 2024.
  • 2023 was a critical year for us and I am pleased to report that we hit all of our intended milestones.
  • As a reminder, MSA is a rare and aggressive Parkinsonian disorder that rapidly progresses and causes profound disability.
  • The pathological hallmark of MSA is accumulation of the protein alpha-synuclein and neuron loss in multiple brain regions within the central nervous system.